Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.20.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Millions
12 Months Ended
Jun. 29, 2020
May 22, 2020
May 31, 2020
May 31, 2019
Commitments and Contingencies [Line Items]        
Common stock, shares issued     519,261,580 329,554,763
Payment of supply commitment     $ 30.0  
Subsequent Event        
Commitments and Contingencies [Line Items]        
Common stock, shares issued 4,000,000      
Common stock converted value $ 22.5      
Project Work Order | Termination of Any One Clinical Trial        
Commitments and Contingencies [Line Items]        
Financial penalties     2.1  
Project Work Order | Termination of Any One Clinical Trial | Minimum        
Commitments and Contingencies [Line Items]        
Financial penalties     0.8  
Project Work Order | Termination of All Clinical Trials | Minimum        
Commitments and Contingencies [Line Items]        
Financial penalties     1.6  
Project Work Order | Termination of All Clinical Trials | Maximum        
Commitments and Contingencies [Line Items]        
Financial penalties     3.6  
Samsung Agreement [Member]        
Commitments and Contingencies [Line Items]        
Supply Commitment Delivered   $ 2.3    
Samsung Agreement [Member] | Manufacturing and Supply Service [Member]        
Commitments and Contingencies [Line Items]        
Supply Commitment Delivered     28.0  
Payments due during calendar year     14.0  
Remaining Supply commitment Cost     116.0  
Obligation Due in Next Twelve Months     69.0  
Obligation Due remainder of fiscal year     23.0  
Obligation Due in Next Two years     $ 24.0